Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 4Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Breast 3Gynecologic 2Gastrointestinal 2CNS 2Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Advanced Malignant Solid Neoplasm 1

Interventions

pembrolizumab 27Pemetrexed 10Nivolumab 10Cyclophosphamide 10Carboplatin 10atezolizumab 8Specimen Handling 8Cisplatin 8Ipilimumab 6Biopsy 6fludarabine 5Injections 5tislelizumab 4spartalizumab 4Vincristine 4Radiotherapy 4Proton Therapy 4Platinum 4Paclitaxel 4Drug Therapy 4Docetaxel 4Bevacizumab 41,2-diaminocyclohexaneplatinum II citrate 4sintilimab 3durvalumab 3Trastuzumab 3Etoposide 3Cetuximab 3zimberelimab 2trametinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × veliparib × Other solid neoplasm × Clear all
NCT01434316 2026-04-13

Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
121 enrolled
Other solid neoplasm

Advanced Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡